Edgewise Therapeutics, Inc. - EWTX STOCK NEWS

Edgewise Therapeutics, a clinical-stage biopharmaceutical company, announced the publication of a significant study in the Journal of Clinical Investigation focusing on EDG-5506 for treating Duchenne and Becker muscular dystrophy. The study indicates that even 15% inhibition of fast skeletal muscle contraction can protect against muscle injury and enhance strength in animal models. With approximately 12,000-15,000 patients in the U.S. affected by DMD, this research highlights the urgent need for effective treatments. EDG-5506 has received Fast Track designation from the FDA and is undergoing clinical trials to assess its efficacy and safety.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, announced that its management will present at the virtual Stifel 2023 CNS Days on March 28, 2023, at 2 pm ET. The presentation will be available via a live webcast, accessible on the Edgewise events page, and will be replayed after the event. Edgewise focuses on therapies for severe muscle disorders, with lead candidate EDG-5506 in trials for Duchenne and Becker muscular dystrophies.

Edgewise Therapeutics (EWTX) announced a podium presentation on March 22, 2023, at the Muscular Dystrophy Association Annual Clinical and Scientific Conference in Dallas, TX. The focus will be on EDG-5506, an investigational therapy for dystrophinopathies like Becker Muscular Dystrophy (BMD). Dr. Han C. Phan will present the 'Effects of EDG-5506 on Biomarkers of Muscle Damage' during the Clinical Trial Updates session. Additionally, Edgewise is hosting an Industry Forum on March 21, 2023, discussing novel approaches to protect muscle in dystrophinopathies, featuring Dr. Barry J. Byrne.

Edgewise Therapeutics (NASDAQ: EWTX) has appointed Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox, currently President and CMO at BridgeBio Pharma and former CMO at MyoKardia, brings extensive experience in cardiovascular clinical development. His expertise will support Edgewise's advancement of EDG-7500, a novel therapy for hypertrophic cardiomyopathy, with a Phase 1 trial expected in late 2023. Dr. Fox's background includes pivotal roles in the development of Camzyos® (mavacamten), emphasizing his capability to boost Edgewise's leadership in cardiovascular therapies.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, will present at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:10 am ET. The presentation will be webcast live, with a replay available afterward. Edgewise focuses on developing small molecule therapies for muscle disorders, including its lead candidate, EDG-5506, which targets dystrophinopathies. The company is also advancing EDG-7500 for hypertrophic cardiomyopathy. Further details can be found on their website.

Edgewise Therapeutics (NASDAQ: EWTX) announced the presentation of EDG-7500, a first-in-class oral therapy for hypertrophic cardiomyopathy (HCM), at the American College of Cardiology's 72nd Annual Scientific Session on March 5, 2023. This investigational drug aims to normalize excess cardiac contraction and improve impaired relaxation, addressing both obstructive and non-obstructive HCM. Key findings include significant improvements in cardiovascular pathophysiologies and potent gradient reductions. The company plans to initiate a Phase 1 trial for EDG-7500 in late 2023, supporting further clinical development based on promising preclinical data.

Edgewise Therapeutics (NASDAQ: EWTX) announced significant advancements in clinical trials for EDG-5506 targeting muscular dystrophies. Phase 2 trials for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) have shown promising developments, with interim data expected in late 2023. The company also initiated IND-enabling studies for EDG-7500, a new treatment for hypertrophic cardiomyopathy, set to begin Phase 1 trials in the second half of 2023. As of December 31, 2022, Edgewise reported cash and marketable securities totaling $352 million and a net loss of $19.4 million for Q4.